Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aravive to Participate in H.C. Wainwright Global Investment Conference
HOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D, DABT, Chief Executive Officer will present at the H.C.
View HTML
Toggle Summary Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates
Reported positive updated data and new biomarker data from Phase 1b Study of Batiraxcept in ccRCC Presented updated modeling data from batiraxcept clinical trials at the AACR annual meeting   Dosed first patient in Phase 2 study of batiraxcept in clear cell Renal Cell Carcinoma  Provided positive
View HTML
Toggle Summary Aravive to Host Key Opinion Leader Symposium on May 11, 2022
HOUSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that it will host a Key Opinion Leader (KOL) Symposium on the GAS6-AXL signaling pathway and the Company’s
View HTML
Toggle Summary Aravive Announces Poster Presentations at the 2022 ASCO Annual Meeting
HOUSTON, April 29, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of two poster abstracts at the upcoming American Society of Clinical Oncology (ASCO) 2022
View HTML
Toggle Summary Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
HOUSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules
View HTML
Toggle Summary Aravive Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates
Reported positive data from Phase 1b trials of batiraxcept in clear cell renal cell carcinoma and pancreatic adenocarcinoma in 1Q’22; on track to report updated data in 2Q’22 Dosed first patient in Phase 2 trial of batiraxcept in ccRCC in January 2022; on track to report preliminary data in 2Q’22
View HTML
Toggle Summary Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
HOUSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced today that it has entered into definitive agreements with a single healthcare-focused institutional investor and
View HTML
Toggle Summary Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
HOUSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of industry veteran, Scott Dove, Ph.D., as Chief Operating Officer. “We are honored Dr.
View HTML
Toggle Summary Aravive to Participate In-Person at 34th Annual ROTH Conference
HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, will participate in an in-person fireside
View HTML
Toggle Summary Aravive Announces Positive Updated Data and New Biomarker Data from Phase 1b Study of Batiraxcept in Clear Cell Renal Cell Carcinoma
46% Best Overall Response Rate in the ITT Population 63% Best Overall Response Rate in the sAXL/GAS6 Biomarker High Population 6-month Progression-Free Survival Rate in the ITT Population of 79% 6-month Progression-Free Survival Rate of 91% in the 15 mg/kg Biomarker High Population 3-month Duration
View HTML